Eli Lilly Offers Obesity Drug Directly to Consumers.
In: Family Practice News, 2024, S. 55-55
Online
Zeitungsartikel
Zugriff:
Eli Lilly, the maker of the anti-obesity drug Zepbound, has launched a direct-to-patient portal called LillyDirect, which allows some patients to obtain the drug for as little as $25 a month. This move is seen as a major shift in how these medications can reach patients. The launch of LillyDirect, along with other developments such as improving insurance coverage and new research on the benefits of weight loss medications, may make 2024 a brighter year for the 42 million Americans with obesity. However, there are concerns about transparency and the potential for confusion among patients. [Extracted from the article]
Copyright of Family Practice News is the property of Frontline Medical Communications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Eli Lilly Offers Obesity Drug Directly to Consumers.
|
---|---|
Autor/in / Beteiligte Person: | Doheny, Kathleen |
Link: | |
Zeitschrift: | Family Practice News, 2024, S. 55-55 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
ISSN: | 0300-7073 (print) |
Schlagwort: |
|
Sonstiges: |
|